A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Trial Profile

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs GSK 3377794 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Adaptimmune
  • Most Recent Events

    • 10 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 15 Mar 2018 According to an Adaptimmune media release, data update from this and other study (NCT02992743: Myxoid/round cell liposarcoma) will be presented at an upcoming congress.
    • 09 Nov 2017 According to an Adaptimmune media release, updated results of all cohorts of the study were presented at the annual CTOS meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top